Han B - Search Results

1

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China.

Xu J, Ding G, Zhang X, Jin B, Lou Y, Zhang Y, Wang H, Wu D, Han B. Xu J, et al. Among authors: han b. Onco Targets Ther. 2016 Oct 20;9:6479-6484. doi: 10.2147/OTT.S119341. eCollection 2016. Onco Targets Ther. 2016. PMID: 27799795 Free PMC article.

2

[Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer].

Gu AQ, Han BH, Zhang XY, Shen J, Qi DJ, Xiong LW, Xin Y, Song YY. Gu AQ, et al. Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):298-301. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 19615288 Clinical Trial. Chinese.

3

[Lung adenocarcinoma stem cell phenotypes and their correlation with patient prognosis].

Zhang XY, Zheng BQ, Han BH, Huang JS, Geng Q, Xu HL, Zhou J, Dong QG. Zhang XY, et al. Zhonghua Zhong Liu Za Zhi. 2009 Nov;31(11):836-40. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 20137348 Chinese.

4

Comparison of PG-SGA, SGA and body-composition measurement in detecting malnutrition among newly diagnosed lung cancer patients in stage IIIB/IV and benign conditions.

Li R, Wu J, Ma M, Pei J, Song Y, Zhang X, Han B. Li R, et al. Among authors: han b. Med Oncol. 2011 Sep;28(3):689-96. doi: 10.1007/s12032-010-9534-z. Epub 2010 Apr 27. Med Oncol. 2011. PMID: 20422319

5

Prognostic significance of OCT4 expression in adenocarcinoma of the lung.

Zhang X, Han B, Huang J, Zheng B, Geng Q, Aziz F, Dong Q. Zhang X, et al. Among authors: han b. Jpn J Clin Oncol. 2010 Oct;40(10):961-6. doi: 10.1093/jjco/hyq066. Epub 2010 May 12. Jpn J Clin Oncol. 2010. PMID: 20462980

6

A clinicopathological study of resected non-small cell lung cancers 2 cm or less in diameter: a prognostic assessment.

Shi CL, Zhang XY, Han BH, He WZ, Shen J, Chu TQ. Shi CL, et al. Med Oncol. 2011 Dec;28(4):1441-6. doi: 10.1007/s12032-010-9632-y. Epub 2010 Jul 27. Med Oncol. 2011. PMID: 20661664

7

[Prognostic Analysis of ERCC1, RRM1 and p53 Expressions in Postoperative Stage I-II Lung Cancer.].

Wang H, Feng J, Zhang X, Yang X, He W, Sha H, Han B. Wang H, et al. Among authors: han b. Zhongguo Fei Ai Za Zhi. 2009 May 20;12(5):387-95. doi: 10.3779/j.issn.1009-3419.2009.05.003. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20719132 Free article. Chinese.

8

[Comparison of the Clinical Effects of Paclitaxel and Paclitaxel plus Oxaliplatin as the Second-line Treatment of Advanced Non-small Cell Lung Cancer.].

Chu T, Lin H, Shen J, Zhong R, Han B. Chu T, et al. Among authors: han b. Zhongguo Fei Ai Za Zhi. 2009 Nov 20;12(11):1178-83. doi: 10.3779/j.issn.1009-3419.2009.11.10. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20723367 Free article. Chinese.

9

The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma.

Zhang XY, Dong QG, Huang JS, Huang AM, Shi CL, Jin B, Sha HF, Feng JX, Geng Q, Zhou J, Xu HL, Han BH. Zhang XY, et al. Among authors: han bh. J Surg Oncol. 2010 Dec 1;102(7):856-62. doi: 10.1002/jso.21718. J Surg Oncol. 2010. PMID: 20818602

10

The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.

Jin B, Huang AM, Zhong RB, Han BH. Jin B, et al. Among authors: han bh. Chemotherapy. 2010;56(6):417-23. doi: 10.1159/000317580. Epub 2010 Nov 16. Chemotherapy. 2010. PMID: 21079400

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,032 results

Search Page

Filters